Related Experiment Videos
[Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells]
1Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Second Medical University, Shanghai 200025.
Objective:
To explore the mechanisms of As2O3 inducing apoptosis and growth inhibition in K562 cells and provide theoretical basis for clinical application.
Methods:
The effects of As2O3 on BCR/ABL protein tyrosine phosphorylation(PTP) and its signal transduction as well as the expression of apoptosis-related genes were studied by means of immunoprecipitation, Western blot, biochemical method and immunofluorescence.
Results:
Tyrosine phosphorylation of several cellular proteins especially BCR/ABL protein was decreased by 1 mumol/L As2O3, but not by 0.1 mumol/L As2O3. As2O3 had no effect on PTP activity, downregulated the expression of JAK2 protein, but did not affect the expressions of STAT1 and STAT2 proteins and the STAT1 protein tyrosine phosphorylation. As2O3 had no effect on the expression of the apoptosis-related genes like Bcl-2, Bcl-xL/S, Bax, ICH-1L, p53, PARP, either, but downregulated PML protein expression in K562 cells.
Conclusion:
As2O3 might induce K562 cell apoptosis and inhibit its growth by reducing tyrosine phosphorylation of cellular proteins especially BCR/ABL protein and/or by downregulating JAK2 protein expression to interfere with the BCR/ABL protein signal transduction.
Insights
Arsenic trioxide (As2O3) induces apoptosis and growth inhibition in K562 cells by reducing BCR/ABL protein tyrosine phosphorylation and JAK2 expression, offering a basis for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is driven by the BCR/ABL oncoprotein.
- Targeting BCR/ABL signaling is a key therapeutic strategy.
- Arsenic trioxide (As2O3) shows potential in cancer treatment.
Purpose of the Study:
- To elucidate the mechanisms by which As2O3 induces apoptosis and growth inhibition in K562 cells.
- To provide a theoretical foundation for the clinical application of As2O3.
Main Methods:
- Immunoprecipitation and Western blot to assess protein expression and phosphorylation.
- Biochemical assays to measure protein tyrosine phosphorylation (PTP) activity.
- Immunofluorescence to study protein localization and expression.
Main Results:
- 1 mumol/L As2O3 decreased BCR/ABL protein tyrosine phosphorylation and JAK2 expression in K562 cells.
- As2O3 did not affect PTP activity, STAT1/STAT2 expression, or STAT1 phosphorylation.
- Downregulation of PML protein expression was observed, while other apoptosis-related genes remained unaffected.
Conclusions:
- As2O3 may induce apoptosis and inhibit K562 cell growth by reducing BCR/ABL protein tyrosine phosphorylation.
- Downregulation of JAK2 protein expression by As2O3 interferes with BCR/ABL signaling.
- These findings support the potential clinical application of As2O3 in CML treatment.